Trends in Treatment for Prostate Cancer in China: Preliminary Patterns of Care Study in a Single Institution

Feng Zhao(Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital), Senxiang Yan(Zhejiang Cancer Hospital), Jiayan Shen(Hangzhou Normal University), Xiaokai Yu(First Affiliated Hospital Zhejiang University), Peng Jiang(Cleveland State University), Baishu Zhong(First Affiliated Hospital Zhejiang University), Guoping Ren(Queen Mary University of London), Jianjian Xiang(Zhejiang University), Zuguo Yuan(First Affiliated Hospital Zhejiang University), Liping Xie(First Affiliated Hospital Zhejiang University)
Journal of Cancer
January 1, 2018
10.7150/jca.25113
Cited by 18

Related Papers

The Lancet Commission on prostate cancer: planning for the surge in cases
|The Lancet|2024|694
YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer
|Molecular Cancer|2020|383
Transperineal versus transrectal prostate biopsy in the diagnosis of prostate cancer: a systematic review and meta-analysis
|World Journal of Surgical Oncology|2019|276
Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies
|BMJ|2014|253
Downregulation of N6-methyladenosine binding YTHDF2 protein mediated by miR-493-3p suppresses prostate cancer by elevating N6-methyladenosine levels
|Oncotarget|2017|207